CJC-1295 (no DAC) (Modified GRF) is a research peptide, also known as Mod GRF (1–29), a tetrasubstituted analog of growth hormone–releasing hormone (GHRH 1–29) engineered for enhanced stability and receptor affinity without Drug Affinity Complex (DAC) conjugation. It activates the GHRH receptor to stimulate adenylate cyclase and cAMP signaling, leading to activation of somatotropic signaling pathways under experimental conditions. Mod GRF (1–29) is used in research focused on peptide pharmacokinetics and pituitary receptor regulation mechanisms.

For research use only. Not for human consumption.

References:
Frohman LA et al., Endocr Rev, 2001;22(6):606–648
Ip E et al., Endocrinology, 2005;146(7):3060–3066
Momany FA et al., Endocrinology, 1981;108(1):31–39

FDA DISCLAIMER

The information provided on this website has not been evaluated by the U.S. Food and Drug Administration (FDA). None of the statements herein, nor any of the products offered, are intended to diagnose, treat, cure, or prevent any medical condition.

All products are supplied strictly as laboratory research reagents and are not for human consumption. We do not provide products to patients and do not make any claims regarding medical use.

PharmaPure Peptide operates solely as a chemical supplier. It is not a compounding pharmacy and does not operate as a compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act.